Advertisement
Research Article| Volume 58, ISSUE 4, P462-468, May 2020

Postoperative risk stratification in oral squamous cell carcinoma

      Abstract

      Postoperative prognostic stratification using the Union for International Cancer Control (UICC) TNM 8th edition staging rules (UICC 8) may identify additional groups of patients who could benefit from adjuvant radiotherapy. Currently, selection for such treatment is not based on all known prognostic factors, and their relative importance may vary depending on the overall risk category. The objective of this study therefore was to evaluate these possibilities. We retrospectively studied 644 patients who had surgery with curative intent for oral squamous cell carcinoma (OSCC) between March 2006 and February 2017. The outcomes of interest were disease-specific survival (DSS) and locoregional recurrence (LRR). Patients were re-staged according to the UICC 8 staging rules. Putative clinical and pathological prognostic variables were evaluated and hazard ratios estimated. Regression analysis was done to identify independent prognostic factors, and iterative analyses identified clinically-relevant risk categories with a minimum of residual prognostic variables. The significance of recognised pathological prognostic factors differed according to the overall risk category. An intermediate risk group comprising patients with pN1 disease as well those with pT3 disease solely on the basis of a depth of invasion (DOI) of more than 10 mm, was identified. A trial to evaluate the benefit or otherwise of adjuvant radiotherapy in this group is now required. Individual prognostic risk factors should be considered within the context of the overall risk category in patients with OSCC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Brierley J.D. Gospodarowicz M.K. Wittekind C. TNM classification of malignant tumours. 8th edition. John Wiley & Sons, 2017
        • Lydiatt W.M.
        • Patel S.G.
        • O’Sullivan B.
        • et al.
        Head and neck cancers - major changes in the American Joint Committee on cancer eighth edition cancer staging manual.
        CA Cancer J Clin. 2017; 67: 122-137
        • Groome P.A.
        • Schulze K.M.
        • Mackillop W.J.
        • et al.
        A comparison of published head and neck stage groupings in carcinomas of the tonsillar region.
        Cancer. 2001; 92: 1484-1494
      2. National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology: cancer of the oral cavity.
        2016
        • Spiotto M.T.
        • Jefferson G.
        • Wenig B.
        • et al.
        Differences in survival with surgery and postoperative radiotherapy compared with definitive chemoradiotherapy for oral cavity cancer – a national cancer database analysis.
        JAMA Otolaryngol Head Neck Surg. 2017; 143: 691-699
        • Wang S.J.
        • Patel S.G.
        • Shah J.P.
        • et al.
        An oral cavity carcinoma nomogram to predict benefit of adjuvant radiotherapy.
        JAMA Otolaryngol Head Neck Surg. 2013; 139: 554-559
        • Cooper J.S.
        • Pajak T.F.
        • Forastiere A.A.
        • et al.
        Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
        N Engl J Med. 2004; 350: 1937-1944
        • Bernier J.
        • Domenge C.
        • Ozsahin M.
        • et al.
        Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
        N Engl J Med. 2004; 350: 1945-1952
        • Bernier J.
        • Cooper J.S.
        • Pajak T.F.
        • et al.
        Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501).
        Head Neck. 2005; 27: 843-850
        • Cooper J.S.
        • Zhang Q.
        • Pajak T.F.
        • et al.
        Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.
        Int J Radiat Oncol Biol Phys. 2012; 84: 1198-1205
        • Shrime M.G.
        • Gullane P.J.
        • Dawson L.
        • et al.
        The impact of adjuvant radiotherapy on survival in T1-2N1 squamous cell carcinoma of the oral cavity.
        Arch Otolaryngol Head Neck Surg. 2010; 136: 225-228
        • Barry C.P.
        • Wong D.
        • Clark J.R.
        • et al.
        Postoperative radiotherapy for patients with oral squamous cell carcinoma with intermediate risk of recurrence: a case match study.
        Head Neck. 2017; 39: 1399-1404
        • Moergel M.
        • Jahn-Eimermacher A.
        • Krummenauer F.
        • et al.
        Effectiveness of adjuvant radiotherapy in patients with oropharyngeal and floor of mouth squamous cell carcinoma and concomitant histological verification of singular ipsilateral cervical lymph node metastasis (pN1-state) – a prospective multicenter randomized controlled clinical trial using a comprehensive cohort design.
        Trials. 2009; 10: 118